Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

NewsGuard 100/100 Score

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

“Cedarlane is recognized for providing the highest quality products to the Life Science community and we're very confident that Cedarlane will provide an extremely effective means to reach our customers”

Cedarlane will become a distributor of TGR's new ELISA-One™ technology assay reagents in Canada and the US. The first 20 ELISA-One™ immunoassay kits for cellular phosphoprotein detection will be available from early 2011, with further additions to the portfolio coming soon after.

"We're extremely pleased to be partnering with such a renowned and trusted company as Cedarlane", says Leanna Read, CEO and Managing Director of TGR BioSciences. "Cedarlane is recognized for providing the highest quality products to the Life Science community and we're very confident that Cedarlane will provide an extremely effective means to reach our customers". "Our new ELISA-One™ assays represent a next generation improvement on what is a traditional workhorse technology in Life Science research laboratories around the world", continues Dr. Read, "It's a familiar technology but one with significant advantages over current ELISAs".

"The ELISA-One™ phosphoprotein assay reagents from TGR will complement very well the quality products that Cedarlane has gained a reputation for carrying for the research community", says Michael DeCosimo, General Manager at Cedarlane. "We see an increasing trend and need for high performance, and yet affordable and simple assays such as ELISA-One™, that address the ever more complex questions that Cell Biology researchers face today".

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breaking through new research barriers with iPSC technology